W STRATEGIES, LLC

Lobbying for SUPERNUS PHARMACEUTICALS FKA SAGE THERAPEUTICS · A clinical-stage biopharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · $50,000.00 income · posted Oct 20, 2025

Lobbying activity 1

Health Issues

Education and awareness of mental health issues especially as it relates to access for postpartum depression treatment and major depressive disorder.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.